Afatinib, a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) family, prevents tumor growth and lymphangiogenesis via inhibiting VEGF-C secretion in the xenograft mouse model of NSCLC [99]. Here, EGFR is linked to non-small cell lung carcinoma.